Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Jeffrey T. Jensen, MD, MPH The effort to reduce the estrogen concentration in combination oral contraceptives (COCs) and strike the right balance between efficacy and safety appears to be never-ending.

Host: Paul Paik, MD Guest: Joshua K. Sabari, MD For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of

Host: Ileana L. Piña, MD, MPH, FAHA, FACC Guest: Javed Butler, MD, MBA, MPH There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fracti

Host: Loretta J. Nastoupil, MD Guest: John P. Leonard, MD Recent clinical trial evidence supports the use of available and emerging options in relapsing/refractory follicular lymphoma. In this case-based activity, Dr. Loretta Nastoupil and Dr. John

Host: David L. Eisenberg, MD, MPH, FACOG Guest: David J. Portman, MD A new form of contraception based on vaginal pH modulation is available. In this activity, Dr. Eisenberg reviews the risks and benefits of the hormone-free, user-controlled gel, a

Guest: D. Ross Camidge, MD, PhD The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to a

Guest: Christie M. Ballantyne, MD Host: John J. Russell, MD According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly dia

Host: Loretta J. Nastoupil, MD Guest: Gilles Salles, MD Follicular lymphoma (FL) is an incurable neoplasm that is frequently associated with relapse and refractory (R/R) disease. In this activity, Drs. Loretta Nastoupil and Gilles Salles will revie

Host: Michael Miller, MD, FACC, FAHA, FNLA Guest: Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC In 2019, the REDUCE-IT trial studying eicosapentaenoic acid (EPA), a purified form of omega-3 fatty acid, was published and demonstrated a dramatic 25% r

Guest: Kevan C. Herold, MD Guest: Stephen Gitelman, MD Experts in the immunopathology of type 1 diabetes consider the potential role of monoclonal antibodies, disease modifying agents, and other agents to prevent or delay the onset of clinical dise